

Food and Drug Administration, HHS

§ 520.38a

- 520.2340 Tepoxalin.
- 520.2345 Tetracycline.
- 520.2345a Tetracycline hydrochloride capsules.
- 520.2345b Tetracycline tablets.
- 520.2345c Tetracycline boluses.
- 520.2345d Tetracycline powder.
- 520.2345e Tetracycline oral liquid.
- 520.2345f Tetracycline phosphate complex and sodium novobiocin capsules.
- 520.2345g Tetracycline hydrochloride and sodium novobiocin tablets.
- 520.2345h Tetracycline hydrochloride, sodium novobiocin, and prednisolone tablets.
- 520.2362 Thenium closylate tablets.
- 520.2380 Thiabendazole oral dosage forms.
- 520.2380a Thiabendazole top dressing and mineral protein block.
- 520.2380b Thiabendazole drench or oral paste.
- 520.2380c Thiabendazole bolus.
- 520.2380d Thiabendazole, piperazine citrate suspension.
- 520.2380e Thiabendazole with trichlorfon.
- 520.2380f Thiabendazole, piperazine phosphate powder.
- 520.2455 Tiamulin.
- 520.2471 Tilmicosin.
- 520.2473 Tioxidazole oral dosage forms.
- 520.2473a Tioxidazole granules.
- 520.2473b Tioxidazole paste.
- 520.2475 Toceranib.
- 520.2481 Triamcinolone acetonide tablets.
- 520.2482 Triamcinolone acetonide oral powder.
- 520.2483 Triamcinolone.
- 520.2520 Trichlorfon oral dosage forms.
- 520.2520b Trichlorfon and atropine.
- 520.2520e Trichlorfon boluses.
- 520.2520f Trichlorfon granules.
- 520.2520g Trichlorfon, phenothiazine, and piperazine dihydrochloride powder.
- 520.2582 Triflupromazine hydrochloride tablets.
- 520.2598 Trilostane.
- 520.2604 Trimeprazine tartrate and prednisolone tablets.
- 520.2605 Trimeprazine tartrate and prednisolone capsules.
- 520.2610 Trimethoprim and sulfadiazine tablets.
- 520.2611 Trimethoprim and sulfadiazine paste.
- 520.2612 Trimethoprim and sulfadiazine suspension.
- 520.2613 Trimethoprim and sulfadiazine powder.
- 520.2640 Tylosin.
- 520.2645 Tylvalosin.

AUTHORITY: 21 U.S.C. 360b.

SOURCE: 40 FR 13838, Mar. 27, 1975, unless otherwise noted.

§ 520.23 Acepromazine.

(a) *Specifications.* Each tablet contains 5, 10, or 25 milligrams (mg) acepromazine maleate.

(b) *Sponsors.* See No. 000010 in § 510.600(c) of this chapter.

(c) *Conditions of use*(1) *Dogs*—(i) *Amount.* 0.25 to 1.0 mg per pound (lb) body weight orally.

(ii) *Indications for use.* As an aid in tranquilization and as a preanesthetic agent.

(iii) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) *Cats*—(i) *Amount.* 0.5 to 1.0 mg/lb body weight orally.

(ii) *Indications for use.* As a tranquilizer.

(iii) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[75 FR 10165, Mar. 5, 2010]

§ 520.28 Acetazolamide sodium soluble powder.

(a) *Specifications.* The drug is in a powder form containing acetazolamide sodium, USP equivalent to 25 percent acetazolamide activity.

(b) *Sponsor.* See No. 053501 in § 510.600(c) of this chapter.

(c) *Conditions of use.* (1) It is used in dogs as an aid in the treatment of mild congestive heart failure and for rapid reduction of intraocular pressure.¹

(2) It is administered orally at a dosage level of 5 to 15 milligrams per pound of body weight daily.¹

(3) For use only by or on the order of a licensed veterinarian.¹

[40 FR 13838, Mar. 27, 1975, as amended at 67 FR 78355, Dec. 24, 2002. Redesignated at 78 FR 66264, Nov. 5, 2013]

§ 520.38 Albendazole oral dosage forms.

§ 520.38a Albendazole suspension.

(a) *Specifications.* Each milliliter of suspension contains 45.5 milligrams

¹These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency and safety information.

§ 520.38b

(mg) (4.55 percent) or 113.6 mg (11.36 percent) albendazole.

(b) *Sponsor*. See No. 000069 in § 510.600 of this chapter.

(c) *Related tolerances*. See § 556.34 of this chapter.

(d) *Special considerations*. See § 500.25 of this chapter.

(e) *Conditions of use*(1) *Cattle*. Administer 11.36 percent suspension:

(i) *Amount*. 4.54 mg/pound (lb) body weight (10 mg/kilogram (kg)) as a single oral dose using dosing gun or dosing syringe.

(ii) *Indications for use*. For removal and control of adult liver flukes (*Fasciola hepatica*); heads and segments of tapeworms (*Moniezia benedeni* and *M. expansa*); adult and 4th stage larvae of stomach worms (brown stomach worms including 4th stage inhibited larvae (*Ostertagia ostertagi*), barberpole worm (*Haemonchus contortus* and *H. placei*), small stomach worm (*Trichostrongylus axei*)); adult and 4th stage larvae of intestinal worms (thread-necked intestinal worm (*Nematodirus spathiger* and *N. helvetianus*), small intestinal worm (*Cooperia punctata* and *C. oncophora*)); adult stages of intestinal worms (hookworm (*Bunostomum phlebotomum*), bankrupt worm (*Trichostrongylus colubriformis*), nodular worm (*Oesophagostomum radiatum*)); adult and 4th stage larvae of lungworms (*Dictyocaulus viviparus*).

(iii) *Limitations*. Do not slaughter within 27 days of last treatment. Do not use in female dairy cattle of breeding age: Do not administer to female cattle during first 45 days of pregnancy or for 45 days after removal of bulls.

(2) *Sheep*. Administer 4.45 or 11.36 percent suspension:

(i) *Amount*. 3.4 mg/lb body weight (7.5 mg/kg) as a single oral dose using dosing gun or dosing syringe.

(ii) *Indications for use*. For removal and control of adult liver flukes (*Fasciola hepatica* and *Fascioloides magna*); heads and segments of common tapeworms (*Moniezia expansa*) and fringed tapeworm (*Thysanosoma actinioides*); adult and fourth stage larvae of stomach worms (brown stomach worm (*Ostertagia circumcincta* and *Marshallagia marshalli*), barberpole worm (*Haemonchus contortus*), small stomach worm (*Trichostrongylus axei*);

21 CFR Ch. I (4–1–14 Edition)

adult and fourth stage larvae of intestinal worms (thread-necked intestinal worm (*Nematodirus spathiger* and *N. filicollis*), Cooper's worm (*Cooperia oncophora*), bankrupt worm (*Trichostrongylus colubriformis*), nodular worm (*Oesophagostomum columbianum*), and large-mouth bowel worm (*Chabertia ovina*)); adult and larval stages of lungworms (*Dictyocaulus filaria*).

(iii) *Limitations*. Do not slaughter within 7 days of last treatment. Do not administer to ewes during first 30 days of pregnancy or for 30 days after removal of rams.

(3) *Goats*. Administer 11.36 percent suspension:

(i) *Amount*. 4.54 mg/lb body weight (10 mg/kg) as a single oral dose using dosing gun or dosing syringe.

(ii) *Indications for use*. For the treatment of adult liver flukes (*Fasciola hepatica*) in nonlactating goats.

(iii) *Limitations*. Do not slaughter within 7 days of last treatment. Do not administer to does during the first 30 days of pregnancy or for 30 days after removal of bucks.

[73 FR 11027, Feb. 29, 2008. Redesignated at 78 FR 66264, Nov. 5, 2013]

§ 520.38b Albendazole paste.

(a) *Specifications*. The product contains 30 percent albendazole.

(b) *Sponsor*. See No. 000069 in § 510.600(c) of this chapter.

(c) *Related tolerances*. See § 556.34 of this chapter.

(d) *Conditions of use in cattle*(1) *Amount*. Equivalent to 4.54 milligrams per 1 pound of body weight (10 milligrams per kilogram).

(2) *Indications for use*. For removal and control of the following internal parasites of cattle; adult liver flukes (*Fasciola hepatica*); heads and segments of tapeworms (*Moniezia benedeni*, *M. expansa*); adult and 4th stage larvae of stomach worms (brown stomach worms including 4th stage inhibited larvae (*Ostertagia ostertagi*); barberpole worm (*Haemonchus contortus*, *H. placei*); small stomach worm (*Trichostrongylus axei*)); adult and 4th stages larvae of intestinal worms (thread-necked intestinal worm (*Nematodirus spathiger*, *N. helvetianus*); small intestinal worm (*Cooperia punctata* and *C. oncophora*)); adult stages of intestinal worms